TSHA
Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
$6.39
+1.91% today
Updated 2026-04-30
Market cap
$1.80B
P/E ratio
—
P/S ratio
184.35x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $7
Volume
2.8M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A5.3
Quality
C+2.5
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-6.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$11.57
+81.06%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 171.30% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -6.12 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-26.97M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.50M | $15.45M | $8.33M | $9.77M | $9.77M |
| Net income | $-166.01M | $-111.57M | $-89.30M | $-109.00M | $-27.85M |
| EPS | — | — | — | — | $-0.34 |
| Free cash flow | $-113.26M | $-80.39M | $-81.60M | $-93.83M | $-26.97M |
| Profit margin | -6,635.25% | -722.06% | -1,071.62% | -1,115.27% | — |
Peer comparison
Smart narrative
Taysha Gene Therapies Inc trades at $6.39. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -6.12, it sits in the distress. TTM revenue stands at $9.77M.
Frequently asked questions
What is Taysha Gene Therapies Inc's stock price?
Taysha Gene Therapies Inc (TSHA) trades at $6.39.
Is Taysha Gene Therapies Inc overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell).
What is the price target of Taysha Gene Therapies Inc (TSHA)?
The analyst target price is $11.57, representing +81.1% upside from the current price of $6.39.
What is Taysha Gene Therapies Inc's revenue?
TTM revenue is $9.77M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
-6.12 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio184.35x
ROE-68.40%
Beta1.08
50D MA$4.92
200D MA$4.32
Shares out0.29B
Float0.20B
Short ratio—
Avg volume2.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—